+ All Categories
Home > Documents > Control and Contamination

Control and Contamination

Date post: 29-Dec-2021
Category:
Upload: others
View: 3 times
Download: 0 times
Share this document with a friend
31
Company Confidential PDA Midwest 13 th Annual Microbial Control and Contamination Cleanroom Validation – Disinfection and Environmental Monitoring September 22, 2021 Joe McCall, SM (NRCM) Director, QA Technical Services ADMA Biologics
Transcript
Page 1: Control and Contamination

Company Confidential

PDA Midwest 13th Annual Microbial Control and Contamination

Cleanroom Validation – Disinfection and Environmental Monitoring

September 22, 2021

Joe McCall, SM (NRCM)

Director, QA Technical Services

ADMA Biologics

Page 2: Control and Contamination

Company Confidential2

Cleanroom Qualification / Validation

Agenda:

Regulatory Perspectives

Best Practices in

• Environmental Monitoring

• Program Development

• Investigations

Page 3: Control and Contamination

3Company Confidential

FDA White Oak Campus

Division of Manufacturing and Product Quality

Office of Compliance and Biologics Quality

Center for Biologics Evaluation and Research

Regulatory Perspectives

Page 4: Control and Contamination

4Company Confidential

Fictional Start-Up Facility – What FDA Investigators should expect to find

Regulatory Perspectives

Inside Info

AGENDA• EM Program Development - Risk Based Approach to Qualification: Site Selection,

Sampling Plan Methods / Frequencies, and Data Handling

– Environmental Qualifications for RABS and Isolators

• EM Data: Understanding the Limits of EM Data w/Special Focus on Excursions and Investigations

Page 5: Control and Contamination

5Company Confidential

CFR Part 211 CGMP for Finished Pharmaceuticals

211.42 Buildings and Facilities

• “The flow…shall be designed to prevent contamination.”• Floors, walls, and ceilings of smooth, hard surfaces that are easily cleanable;• (ii) Temperature and humidity controls;• (iii) An air supply filtered through high-efficiency particulate air filters under positive pressure,

regardless of whether flow is laminar or nonlaminar;• (iv) A system for monitoring environmental conditions;• (v) A system for cleaning and disinfecting the room and equipment to produce aseptic

conditions;• 211.46• Equipment for adequate control over air pressure, micro-organisms, dust, humidity, and

temperature…

Regulatory Expectations

Page 6: Control and Contamination

6Company Confidential

Guidance and Standards: What should be expected of Cleanroom Manufacturers?

ISO 14644 / 2004 FDA CGMP

ISO 14644 Cleanrooms and Associated Controlled Environments –

• Part 1 (2015): Classification of Air Cleanliness by Particle Concentration

• Part 2 (2015): Monitoring to Provide Evidence of Cleanroom Performance Related to Air Cleanliness by Particle Concentration

• A risk assessment shall be undertaken in order to:

• - develop a monitoring plan by determining the factors that may affect the ability to maintain the agreed air cleanliness by particle concentration of the cleanroom or clean zone

• - determine the monitoring requirements to provide evidence of performance

Regulatory Expectations

Page 7: Control and Contamination

7Company Confidential

Industry

No excuse for not knowing

• PDA

• PIC/S

• IEST

• ISPE

• PMF

• BPOG

• ASM

• …

Guidance and Standards: What should be expected of Cleanroom Manufacturers?

Regulatory

• EU Guidelines to CGMP for Medicinal Products Annex 1

• 2004 FDA CGMP Guidance for Industry Sterile Drug Products Produced by Aseptic Processing

• USP <1116> Microbiological Control and Monitoring of Aseptic Processing Environments

Page 8: Control and Contamination

8Company Confidential

Annex 1…revision

• 15 pages…to 50

• 127 clauses…to 269

• Mention of “risk” from 20 times…to 92

• References to “Risk Assessment” and “Risk Management” throughout

Regulatory Expectations

“Clean rooms and clean air devices should be routinely monitored in operation and the monitoring locations based on a formal risk analysis study and the results obtained during the classification of rooms and/or clean air devices.”

Page 9: Control and Contamination

9Company Confidential

USP <1116> Microbiological Control and Monitoring of Aseptic Processing Environments

“Monitoring locations should be based upon an assessment of risk.”

In case there was any doubt…

Page 10: Control and Contamination

10Company Confidential

Historical Current (better!)

• Based on higher risk aseptic processes & opinion, ambiguous selection criteria

• Program tailored to specific facility and processes; criteria based on objective risk-based approaches

Risk based Approach to Site Selection, Sampling Plan Methods / Frequencies & Data

Page 11: Control and Contamination

11Company Confidential

Risk Based Approach to: Site Selection, Sampling Plan Methods / Frequencies, & Data

•Cross-functional Group Project: Led by SMEs in Pharmacuetical Microbiology / Contamination Control

• Identify Risk Factors for Process & Area

• In-person Assessment of Risks: Process & Area

EM Program Development

•FMEA / Flow Charts / HACCP / Process Mapping

Page 12: Control and Contamination

12Company Confidential

Risk Based Approach to: Site Selection, Sampling Plan Methods / Frequencies, & Data

• Map the Area

• Grid overlay

• Specify Critical Functional Areas

• Suggest defining grid size by ISO classification (5, 7, 8) or Grade (ABCD)

EM Program Development

Page 13: Control and Contamination

13Company Confidential

Risk Based Approach to: Site Selection, Sampling Plan Methods / Frequencies, & Data

Map the Area

Grid overlay

Specify Critical Functional Areas

Suggest defining grid size by ISO classification (5, 7, 8) or Grade (ABCD)

EM Program Development

Examples:

• 0.5 m2 Grade A

• 4.0 m2 for B, C, D

or

• Grade A 1m2, Grade B 2m2, Grade C 3m2 and Grade D 4m2

Page 14: Control and Contamination

14Company Confidential

Risk Criteria Rationalized Frequency

• Easy to Clean / Sanitize / Disinfect / Sterilize

• Proximity of Open Product or Product-Contact Parts

• Material Flow

• Personnel Presence & Movement

• Interventions: complex, simple, prolonged, routine, non-routine

• Nature & frequency of Interventions, Process Steps

• Based in principles of Risk, Science, & Logic

• 2 Factors most heavily weighed for Frequency

• Probability of Contamination

• Potential for Impact to Product Quality

• Differentiate by Grade

• Differentiate by Function

• High Traffic Areas – Material Pass-Through and Personnel Entryways

• Differentiate Floors, Walls, Ceilings, Equipment, Touch Points

Site Selection / Sampling Plan

Page 15: Control and Contamination

15Company Confidential

General Attributes

• Follows a written & approved sampling plan– Traceability

• Performed by qualified / trained samplers

• Defined number of “rounds”

• At-Rest / In-Operation

• Acceptance Criteria– If initial EM qualification, may be informational or target levels

• Response, Resolution, Remediation

Implementation

Page 16: Control and Contamination

16Company Confidential

EM Program – Can it demonstrate recovery after a loss of control, planned or unplanned?

Need to have a written plan

FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice (Sept. 2004 Pharmaceutical CGMPs)

• “Deviation or change control systems should address atypical conditions posed by shutdown of air handling systems or other utilities, and the impact of construction activities on facility control. Written procedures should address returning a facility to operating conditions following a shutdown.”

Question:

Page 17: Control and Contamination

17Company Confidential

Environmental Qualifications for Isolators

Traditional EM design principles are inappropriate

Far lower or better rates of contamination thantraditional cleanroom

Additional equipment, sampling, etc. in a confined space with exceptional control

Spatial limitations

Non value-added monitoring increases cost & resource consumption

Advanced Aseptic Processing Technology

Page 18: Control and Contamination

18Company Confidential

Test Results, Excursions, and Investigations

Principles to Avoid the Over-, Under-, and Mis-interpretation

of EM Data

Understanding the Limits of EM Data

Page 19: Control and Contamination

19Company Confidential

Understanding the Limits of EM Data w/Special Focus on Excursions and Investigations

Cultivation-based Sampling

Accuracy at low levels (<25 CFU) is poor

Variability

EM Data Limits

Page 20: Control and Contamination

20Company Confidential

The Great Plate Anomaly

Cultivation-Based Microbiology

~100 times more cells than colonies ≈ 99% “unculturable”

• Annu Rev Microbiol. 1985;39:321-46.

• Measurement of in situ activities of nonphotosynthetic microorganisms in aquatic and terrestrial habitats.

• Staley JT, Konopka A

Page 21: Control and Contamination

21Company Confidential

LIMITS

0 – 60% Recovery

Dependent on Surface Type

Dependent on Operator Technique

Dependent on…

• Condition of microbe

• Temperature

• Humidity

• Media type

• Exposure time

• Incubation time

etc.

Understand Inherent Variability and Imprecision

Page 22: Control and Contamination

22Company Confidential

Relevance of Sampling Method

Don’t overinterpret those 0 CFUs

25 cm2 contact plate in a 10’ x 10’ Room

1 floor plate = 0.03% of surface area

Page 23: Control and Contamination

23Company Confidential

“Zero” Significance

Adapted from “Regulation of Aseptic Processing in the 21st Century”, 2011, Pharmaceutical Technology, Akers & Agalloco

Example of over-interpreting “0 CFU” results from EM

• 500 Air Changes per hour

• Cleanroom area of 500 m3

• Total volume of air = 250,000/m3 of air per hour

1,000 instruments each collecting 6 m3/hour could sample 6,000 m3 out of 250,000 m3…

…or just 0.24%

Page 24: Control and Contamination

24Company Confidential

Where to Begin?

– Manned cleanrooms and work zones have microbial presence

– Systemic failures should have demonstrable causes

– Deviations from Standard Operating Procedure are risky

– Breach in primary control system(s) is a probable RC

– Involvement of Microbiology• Identification of contaminant(s)• Review of EM and relevant test histories

– Batch Record Review– Training records– Method validation

Investigations

Page 25: Control and Contamination

25Company Confidential

Assess Validity of Sample Causes of Bad Investigations

• Sample collection

• Relevant Associated Testing? (warning, pitfall here)

• Sample Transport, Chain of Custody maintained?

• Appropriate Sample Storage Conditions?

• Analyst Qualification, Training, and Experience Level?

• Test Equipment Validated and Calibrated? Good Working Order?

• Assumption is still too pervasive that an aseptic processing environment is sterile, or at least must yield EM data that signifies sterility

• Ascribing qualities to microbial data that it does not possess over and under interpretation of EM data is common

• Seeing “patterns” or “trends” where no meaningful correlation exists

• Pressure to identify palatable RC

Site Selection / Sampling Plan

Page 26: Control and Contamination

26Company Confidential

Evaluate Cleaning & Disinfection Program as a potential cause

• Disinfectant application conditions

• Time / Temperature

• Application method

• Personnel – experience, technique

• Water quality

• Extra shift

• New personnel

• Construction

• Chemical agent (conc., product quality)

Site Selection / Sampling Plan

Page 27: Control and Contamination

27Company Confidential

Optimized Pitfalls

• Operator interviews

• First-hand observations

• Senior Management Support

• Empowered engaged employees

• Lack of true subject matter experts on staff

• Misapplication of technologies

• Misunderstanding of test methods

• Depth and breadth of staff experience

• Status Quo

EM Investigations

Page 28: Control and Contamination

28Company Confidential

Holmes, Ockham & Logical Fallacies

Sherlock Holmes, “…when you have eliminated the impossible, whatever you’re left with, however improbable, is the truth.” The Sign of the Four, ch. 6 (1890), Sherlock Holmes in The Sign of the Four (Doubleday p. 111)

Investigations

William of Ockham, 14th century Franciscan friarNotable for problem-solving principle that states "entities should not be multiplied unnecessarily”Ockham’s Razor or "the law of briefness"

Page 29: Control and Contamination

29Company Confidential

Logical Fallacies

AVOID THESE!

Investigations

Appeal to Probability

Post hoc ergo propter hoc

– After this, therefore because of this

Correlation Proves Causation

Cherry picking

Slippery slope

Appeal to Authority

Ad hoc hypothesis

Page 30: Control and Contamination

30Company Confidential

Takeaways

Our biopharma company must have a qualified EM program for their facility

Developed and established using principles and tools of Risk Management

Cleanroom operators must understand microbiology and contamination control principles.

All personnel must receive initial and periodic training in aseptic processing, interventions, gowning, contamination control.

This training MUST be delivered by Subject Matter Expert(s), proficient in the topics they teach.

Data and Investigations of microbial contamination issues need to be looked at through different lens.

Page 31: Control and Contamination

31

Thank You

Company Confidential


Recommended